Alternative Cancer Treatment | Cancer Cure | Cancer Remedies

Although this is an orthodox chemotherapy treatment, it is substantial news, and I decided to speak about it nevertheless because of the high scrutiny under which Avastin (bevacizumab) has been subjected.  This substance already has approval for a variety of cancers, such as colon, brain, kidney, and lung cancers.

Bevacizumab (Avastin) works by blocking angiogenesis (i.e., the growth of new blood vessels that enable tumors to grow).  It is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). It was the first angiogenesis inhibitor available in the United States for clinical applications.  It received its first approval for cancer treatment in 2004 when used in combination with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. continue reading…

Dr. McLaughlin summarizes the clinical results of the cancer research performed with the use of Paw Paw substances.

The clinical studies were done on breast cancer, prostate cancer, lymphoma non-Hodgkin’s, stage 4 lung cancer and melanoma. The results were very good, very promising.  It appeared that most cancer patients were using Paw Paw in conjunction with conventional cancer treatments. continue reading…

Dr. McLaughlin discussed the scientific findings of his studies on Paw Paw compounds.  He also summarizes the effects and method of action of the acetogenins.

There are over 100 scientific papers on the chemistry and biological effects of Paw Paw. It was also found that the Zebra Swallowtail butterfly eats the leaves of the Paw Paw plant.  That butterfly is an obligate parasite of the plant. It constitutes a defense mechanism for the butterfly because birds that eat them become nauseous and vomit. continue reading…

I came across a report that claims that the anticancer drug, Avastin, can help ovarian cancer patients.  The drug, which is commonly used to treat colon, breast and brain cancers, now may have an application in ovarian cancer.

Researchers added Avastin to a standard chemotherapy and maintenance regimen to a group of women with cancer of the ovaries or closely related areas. They found that the women who were given Avastin lived an average of four months longer without the disease progressing than those who did not receive it.

Avastin is not without a level of controversy in its history.  Some experts objected to FDA approval of it for metastatic breast cancer because the drug only slows tumor growth, but fails to extend survival.  The FDA approved it for use anyway, even though a panel of outside advisers voted 5 to 4 against approval.  Although Avastin reduces tumor size and shows an increase in progression-free survival time, it does not prolong or increase the quality of life for late-stage cancer patients. continue reading…